Business
Capricor Therapeutics Announces New Advances in Exosome-Mediated mRNA Delivery Platform
-New Data Demonstrates Exosome-Mediated Delivery of mRNAs With Enhanced Expression and Lower Toxicity Compared to Lipid Nanoparticles- -Functional Enzyme
About this update from Capricor Therapeutics, Inc.
[{"type":"text","content":"-New Data Demonstrates Exosome-Mediated Delivery of mRNAs With Enhanced Expression and Lower Toxicity Compared to Lipid Nanoparticles- -Functional Enzyme Expression and Real-Time Imaging of mRNA Expression in Live Animals- -Platform for Advancing Clinical Development of Exosome-RNA Based Vaccine Candidate- -Data to be Discussed on Earnings Call this Thursday, March 11 at 4:30 p.m. ET- LOS ANGELES, March 09, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, in collaboration with researchers, announced today that new advances from its positive preclinical study for a multivalent exosome-based mRNA vaccine for COVID-19 have been posted on the bioRxiv preprint server and has been submitted for publication. “Capricor previously demonstrated that our exosome-based multivalent RNA delivery platform can induce long-lasting immune responses to multiple SARS-CoV-2 proteins, and potentially elicit a broad-based, cellular and humoral immunity. We decided to explore further the expression of RNAs with our exosome-based delivery system and compare exosomes with lipid nanoparticles specifically focused on short term toxicity,” said Linda Marbán, Ph.D., CEO of Capricor. “The data demonstrated functional RNA expression in vivo further showing the power of our exosome platform to potentially expand into areas beyond SARS-CoV-2. This strengthens my belief that our exosome platform can deliver RNA effectively into cells and drive the expression of functional proteins. The opportunities for pipeline expansion are very exciting, both in vaccines and in the delivery of therapeutic RNAs.” Key takeaways from this pre-clinical study include: Real-time imaging establishing exosome-mediated mRNA expression in living animalsDemonstration that exosome-mRNA formulations can drive functional enzyme expression in vivo, opening the opportunity for therapeutic exosome-mRNA formulationsSuperior expression from exosome-mRNA formulations compared to Lipid Nanoparticle (LNP)-mRNA formulationsExosome-mRNA treatment and exosome injections are free of adverse effects, in contrast to LNP-mRNA treatments and LNP injections Exosomes are the body’s own drug delivery vehicle, produced by...